Current Strategies for the Development of Novel Antipsychotic Drugs

Author(s): Jordi Bolos

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 3 , Issue 3 , 2003

Become EABM
Become Reviewer
Call for Editor


While classical neuroleptics are characterized by dopamine D2 antagonism, this is also considered to be the cause of their neurological side effects. In recent years, novel antipsychotic drugs with improved efficacy, devoid of extrapyramidal effects are being developed. The mechanisms of action of these new atypical antipsychotics can be classified into three general groups: a) binding to D2 together with non-dopaminergic receptors, b) interaction with dopamine receptor subtypes other than D2 and c) selective binding to nondopaminergic systems, such as glutamatergic, sigma, neurotensin, and cannabinoid.

Keywords: Antipsychotic Drugs, D2 antagonism, dopamine receptor, neurotensin, glutamatergic, nondopaminergic

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2003
Page: [239 - 251]
Pages: 13
DOI: 10.2174/1389557033488169
Price: $65

Article Metrics

PDF: 4